U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C8H15O2.Zn
Molecular Weight 351.816
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC CAPRYLATE

SMILES

[Zn++].CCCCCCCC([O-])=O.CCCCCCCC([O-])=O

InChI

InChIKey=CHJMFFKHPHCQIJ-UHFFFAOYSA-L
InChI=1S/2C8H16O2.Zn/c2*1-2-3-4-5-6-7-8(9)10;/h2*2-7H2,1H3,(H,9,10);/q;;+2/p-2

HIDE SMILES / InChI
Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C8H15O2
Molecular Weight 143.2035
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity

There is no available information related any biological or pharmacutical application of AMMONIUM PENTACHLOROZINCATE

CNS Activity

Originator

Protherics
40
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

1921
1447
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8228
Activator
1410
Activator
1410
Hydrolytic Enzyme
38
Target ID: ultraviolet B-induced damage
Interacts
321
Activator
1410
Zinc transporter ZIP1
38
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Binding Agent
1059
Zinc transporter ZIP2
38
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Binding Agent
1059
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8360
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

-4.55328006E11
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Secondary
Approved
8360
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

1.32675836E12
Primary
Approved
8360
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

1.140048E12
Primary
Approved
8360
ZINC OXIDE

Approved Use

Unknown
Primary
Approved
8360
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
Phase III
663
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
Phase III
663
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
PubMed

PubMed

TitleDatePubMed
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.
1991 Apr 1
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
1997 Feb
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide.
1997 May 16
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study.
1999 May
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.
2004
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.
2004 Jul 16
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.
2004 Jul 30
Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2.
2005 Apr 27
Elevated cortical zinc in Alzheimer disease.
2006 Jul 11
Zinc homeostasis in aging: two elusive faces of the same "metal".
2006 Summer
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
2007 Nov
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.
2010 Oct
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.
2013 Dec
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.
2014 Jan
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014 May 16
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.
2014 May 16
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Patents

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
Rats: The dose of zinc hydroxide administered to each rat was 85 mg/kg and represented 40% of the recommended daily allowance of a male adult human. This dose was administered in water solution at a final volume of 1 mL per rat.
Route of Administration: Oral
In Vitro Use Guide
Zinc hydroxide (1 mM) stimulates superoxide production by rat alveolar macrophages, as determined by CLA-dependent chemiluminescence.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:33:13 UTC 2023
Edited
by admin
on Wed Jul 05 22:33:13 UTC 2023
Record UNII
QL5435GI2S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC CAPRYLATE
MI  
Systematic Name English
OCTANOIC ACID, ZINC SALT (2:1)
Common Name English
OCTANOIC ACID ZINC SALT
Common Name English
ZINC OCTANOATE
Systematic Name English
ZINC CAPRYLATE [MI]
Common Name English
NSC-63869
Code English
Classification Tree Code System Code
NCI_THESAURUS C737
Created by admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
Code System Code Type Description
NSC
63869
Created by admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
PRIMARY
NCI_THESAURUS
C84246
Created by admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
PRIMARY
FDA UNII
QL5435GI2S
Created by admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
PRIMARY
ECHA (EC/EINECS)
209-156-6
Created by admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
PRIMARY
PUBCHEM
11180
Created by admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
PRIMARY
EPA CompTox
DTXSID2042517
Created by admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
PRIMARY
CAS
557-09-5
Created by admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
PRIMARY
MERCK INDEX
M11599
Created by admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
PRIMARY Merck Index
Related Record Type Details
Structure of CAPRYLIC ACID
PARENT -> SALT/SOLVATE
Structure of ZINC CATION
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ZINC CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966